SCHEMBL22513706

SCHEMBL22513706

Cc1n[nH]c2ccc(-c3ccc(C(C)C)cc3)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 7/20 0.51
MKNK1 Q9BUB5 1/20 0.49
DYRK1A Q13627 6/20 0.42
PDPK1 O15530 2/20 0.41
PRKAG1 P54619 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PRKAB1 Q9Y478 1/20 0.40
CDC7 O00311 1/20 0.40
PLK4 O00444 1/20 0.40
DAPK3 O43293 1/20 0.40
DYRK3 O43781 1/20 0.40
ROCK2 O75116 1/20 0.40
PRKD3 O94806 1/20 0.40
MAP4K4 O95819 1/20 0.40
CDK1 P06493 1/20 0.40
ROS1 P08922 1/20 0.40
CDK2 P24941 1/20 0.40
MARK3 P27448 1/20 0.40
TYK2 P29597 1/20 0.40
KDR P35968 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL84556 0.86 ADORA2A (0.43) JAK2MKNK1DYRK1ADAPK3MAP4K4
SCHEMBL19188029 0.83 JAK2 (0.57) JAK2MKNK1DYRK1APDPK1PRKAG1
SCHEMBL27968550 0.81 MKNK1 (0.71) JAK2MKNK1DYRK1APRKAG1PRKAA1
SCHEMBL12907439 0.80 MAPK1 (0.59) JAK2MKNK1DYRK1APDPK1PRKAG1
SCHEMBL22339348 0.77 JAK2 (0.51) JAK2MKNK1PDPK1PRKAG1PRKAA1
SCHEMBL22513720 0.76 JAK2 (0.50) JAK2MKNK1DYRK1APDPK1PRKAG1
SCHEMBL16076615 0.76 KIF11 (0.47) JAK2DYRK1APDPK1DAPK3MAP4K4
SCHEMBL25194999 0.74 CCNC (0.69) JAK2DYRK1ACLK2NPSR1
SCHEMBL29942349 0.73 MAP2K4 (0.64) JAK2MKNK1DYRK1APRKAA1DAPK3
SCHEMBL12907433 0.73 MKNK1 (0.51) JAK2MKNK1DYRK1ACDK2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-12-20 US disclosed
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11530209-B2 Small molecule inhibition of transcription factor SALL4 and uses thereof SALL4, GLI2, TCF4 JAK2 1354/4885MKNK1 1178/4885DYRK1A 3768/4885
US-20200317664-A1 SMALL MOLECULE INHIBITION OF TRANSCRIPTION FACTOR SALL4 AND USES THEREOF SALL4, GLI2, TCF4 JAK2 1354/4885MKNK1 1178/4885DYRK1A 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.